COMPASS Pathways
CMPS | NASDAQ
$8.27
-$0.74 (-8.21%)
At close: Nov 16, 2026, 4:00 PM ET
$8.33
+$0.06 (+0.69%)
After-hours:
Nov 16, 2026, 7:53 PM ET
COMPASS Pathways Company Profile
Company profile explainedCompany Profile
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Key Executives
| Name | Position |
|---|---|
| Kabir Nath | Chief Executive Officer & Director |
| Kelley Boucher | Chief People Officer |
| Teri Loxam | Chief Financial Officer |
| Benjamin Harber | Company Secretary |
| Guy Goodwin | Chief Medical Officer |
| Lars Christian Wilde | Senior Advisor |
| Lori Englebert | Chief Commercial Officer |
| Michael Gold | Chief Research & Development Officer |
| Stephen D. Schultz | Senior Vice President of Investor Relations |
| Steve Levine | Chief Patient Officer |
| Susan C. Stansfield | Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | S-3ASR | Automatic shelf registration statement of securiti... |
| Aug 05, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Jul 07, 2026 | 8-K | Current Report |
| May 29, 2026 | 4 | Filing |
| May 29, 2026 | 4 | Filing |
| May 29, 2026 | 4 | Filing |
| May 29, 2026 | 4 | Filing |
COMPASS Pathways
| Country | United Kingdom |
| IPO Date | Sep 18, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 156 |
| CEO | Kabir Kumar Nath |
Contact Details
33 Broadwick Street London,
CH W1F 0DQ United Kingdom
Stock Details
| Ticker Symbol | CMPS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001816590 |
| CUSIP Number | 20451W101 |
| ISIN Number | US20451W1018 |
| SIC Code | 2834 |
Recent News
- 4 days ago / marketbeat.comCompass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
- 5 days ago / businesswire.comCompass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
- 8 days ago / businesswire.comCompass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression
- 13 days ago / businesswire.comCompass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
- 13 days ago / fool.comCompass Pathways: 3 Key Takeaways for Long-Term Investors
- 14 days ago / seekingalpha.comCOMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
- 15 days ago / businesswire.comNew Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers
- 15 days ago / fool.com1 Reason Compass Pathways Is Worth a Second Look This Month
- 20 days ago / businesswire.comCompass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress
- 20 days ago / seekingalpha.comCompass Pathways: A Compelling Opportunity In A Large And Underserved Market
Add to Watchlist
Select watchlists to add or remove CMPS